Mr. Dickey is an accomplished financial professional with senior leadership experience in private and public healthcare companies. Prior to joining Motif Bio, he was CFO at Tyme Technologies Inc., a NASDAQ-listed clinical stage oncology company. Robert previously held senior leadership positions at NeoStem, Inc. (now known as Caladrius Biosciences Inc.), Hemispherx Biopharma Inc., Stemcyte Inc., Locus Pharmaceuticals Inc. and Protarga Inc. Mr. Dickey began his career as an Investment Banker at Lehman Brothers and Legg Mason Wood Walker Inc.
Nucleic acid manufacturer Nitto Denko Avecia has agreed to buy Irvine Pharmaceutical Services and Avrio Biopharmaceuticals in deals designed to expand its production business.
Hemispherx Biopharma has hired Avrio Biopharmaceuticals to make Ampligen while it continues to try and win US approval for rejected candidate chronic fatigue syndrome (CFS) drug candidate.
William Carter, the chairman, chief executive officer, and chief scientific officer of Philadelphia-based Hemispherx Biopharma recently had to give back an unspecified number of securities to the company.
Hemispherx Biopharma has had a somewhat rocky relationship with both the FDA and the Street. But with a manufacturing upgrade complete and a distribution agreement in hand, it expects to return to the market its only approved product after a 7-year hiatus.